Clinical Use of Genetic Polymorphisms as Markers of Refractoriness in Schizophrenia

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBILL, Martinus T. van de
dc.contributor.authorPRADO, Carolina M.
dc.contributor.authorOJOPI, Elida P. B.
dc.contributor.authorLOCH, Alexandre A.
dc.contributor.authorZANETTI, Marcus V.
dc.contributor.authorSOUSA, Rafael A. T.
dc.contributor.authorMACHADO-VIEIRA, Rodrigo
dc.contributor.authorGATTAZ, Wagner F.
dc.date.accessioned2013-10-11T21:25:22Z
dc.date.available2013-10-11T21:25:22Z
dc.date.issued2012
dc.description.abstractBackground: Pharmacogenetics studies have demonstrated the importance of various neurotransmitter systems in mediating drug effectiveness. Due to the importance of the dopaminergic system in the activity of antipsychotics, proteins that regulate the availability of dopamine may influence the response to drug treatment, as the enzyme catechol-O-methyl-transferase (COMT), which catalyzes the breakdown of dopamine. Some associations have already been described between Val108/158Met polymorphism and response, with individuals carrying the Met allele presenting the best answer. However, most of the findings reported have not been universally replicated. Methods: The study enrolled 89 schizophrenia patients divided in two groups: 59 refractory patients according to IPAP algorithm (International Psychopharmacology Algorithm Project) and 30 non-refractory patients. Polymorphisms in COMT (rs4680), HTR2A (T102C, rs6314, rs1928042), HTR2C (rs6318, rs3813929), CHRNA7(rs7164043), BDNF (rs6265), DRD3 (rs6280) and GRM8 (rs7778604) genes were evaluated by allelic discrimination using the TaqMan® system. Results: regarding the polymorphism rs4680 (Val158Met) of the COMT gene, among the non-refractory patients we found 7% AA, 50% AG and 43% GG genotypes. Among refractory patients we found 20% AA, 59% AG and 21% GG. After the X2 test, we found a difference in the genotype distribution between the two groups (p=0.043). For the other polymorphisms in genes HTR2A, HTR2C, CHRNA7, BDNF, DRD3, and GRM8, no significant difference was found. Conclusions: Our findings do not confirm previous data. In our study there is a higher prevalence of individuals homozygous for Met in the refractory group and a higher prevalence of individuals homozygous for Val the non-refractory (p=0.043).
dc.description.conferencedateMAY 03-05, 2012
dc.description.conferencelocalPhiladelphia - PA, EUA
dc.description.conferencename67th Annual Meeting of the Society-of-Biological-Psychiatry
dc.description.indexMEDLINE
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2009/17960-1
dc.identifier.citationBIOLOGICAL PSYCHIATRY, v.71, n.8, suppl.S, p.158S-158S, 2012
dc.identifier.issn0006-3223
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2966
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofBiological Psychiatry
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCIENCE INC
dc.subjectSchizophrenia
dc.subjectRefractoriness
dc.subjectPharmcogenetics
dc.subjectPharmacodynamics
dc.subjectCOMT
dc.subject.wosNeurosciences
dc.subject.wosPsychiatry
dc.titleClinical Use of Genetic Polymorphisms as Markers of Refractoriness in Schizophrenia
dc.typeconferenceObject
dc.type.categorymeeting abstract
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcMARTINUS THEODORUS VAN DE BILT
hcfmusp.contributor.author-fmusphcCAROLINA MARTINS DO PRADO
hcfmusp.contributor.author-fmusphcALEXANDRE ANDRADE LOCH
hcfmusp.contributor.author-fmusphcMARCUS VINICIUS ZANETTI
hcfmusp.contributor.author-fmusphcRAFAEL AUGUSTO TEIXEIRA DE SOUSA
hcfmusp.contributor.author-fmusphcRODRIGO MACHADO VIEIRA
hcfmusp.contributor.author-fmusphcWAGNER FARID GATTAZ
hcfmusp.description.beginpage158S
hcfmusp.description.endpage158S
hcfmusp.description.issue8
hcfmusp.description.issuesuppl S
hcfmusp.description.volume71
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:000302466000497
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.remissive.sponsorshipFAPESP
relation.isAuthorOfPublicatione66f1d29-2fed-4486-a0ab-6de56f685ce8
relation.isAuthorOfPublicationd7e5590c-2e92-4a03-a558-6ee1110835dd
relation.isAuthorOfPublicatione5114830-117e-4f3c-95a4-5feabffc15b7
relation.isAuthorOfPublicationc0e3a2b2-9a34-4116-9da9-75bec7265484
relation.isAuthorOfPublication9fc9d7cc-a262-4fb6-a447-fbc1dad7c205
relation.isAuthorOfPublication87bd8384-b428-475b-b25d-011a60f9d83c
relation.isAuthorOfPublication125dcc9f-a05a-42fd-ab1d-b6db35d2616b
relation.isAuthorOfPublication.latestForDiscoverye66f1d29-2fed-4486-a0ab-6de56f685ce8
Arquivos
Coleções
Comunicações em Eventos - FM/MPS
Comunicações em Eventos - HC/IPq
Comunicações em Eventos - LIM/21
Comunicações em Eventos - LIM/23
Comunicações em Eventos - LIM/27